# Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency

> **NCT02908958** · PHASE4 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 900 (estimated)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **BIOLOGICAL:** PEG-somatropin
- **BIOLOGICAL:** PEG-somatropin

## Key facts

- **NCT ID:** NCT02908958
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2017-06
- **Final completion:** —
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908958, "Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02908958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*